NCT02213289: PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression
- State
- Completed
- Phase
- Phase 2
- People
- 80 taking part
- Started
- 20 Jan 2015
- Primary completion
- 1 Feb 2020
- Arms
- ITT-PTS: Personalized Treatment Strategy (MAPK/PIK3CA aberrant), ITT-PTS: Personalized Treatment Strategy (All negative)
- Results
- Posted on the registry
- 11 Aug 2014: Trial registered
- 20 Jan 2015: Trial started
- 20 Aug 2020: Trial completed
- 8 Apr 2021: Trial results posted